Evaluating the Safety and Efficacy of Ocriplasmin in Pediatric Versus Adult Ophthalmology: A Systematic Review and Meta-Analysis

Abstract

Introduction: This study assessed the safety and efficacy of ocriplasmin in pediatric ophthalmology, focusing primarily on pediatric patients. It also considered adult cases to address specific aspects of its safety and effectiveness.Methods: This systematic literature review was conducted following the PRISMA guidelines, incorporating 15 articles that included 901 cases in the ocriplasmin group and 529 cases in the ALG-1001 group within pediatric populations. The review compared the effectiveness and safety of ocriplasmin in pediatric ophthalmology to that of ALG-1001, focusing on outcomes such as vitreomacular adhesion (VMA) release, macular hole (MH) closure, and vitreomacular traction (VMT) release.
Results: The study findings revealed that ocriplasmin demonstrated a higher MH closure rate (OR=3.16; 95% CI: 1.29-7.42; P=0.044) compared to ALG-1001. Additionally, ocriplasmin had a higher VMA release rate (OR=2.92; 95% CI: 1.31-7.52; P=0.022) and VMT release rate (OR=3.51; 95% CI: 1.43-7.13; P=0.002). There were no complications associated with ocriplasmin use among pediatric patients.
Conclusion: This meta-analysis affirms ocriplasmin’s safety and efficacy in pediatric ophthalmology, surpassing ALG-1001 for VMT, MH, and VMA. Despite the limitations in existing literature, ocriplasmin proves more effective, indicating potential clinical utility for challenging cases with strong adhering Posterior Vitreous Detachment (PVD), where vitrectomy is difficult.